Leerink Partnrs Issues Pessimistic Estimate for LLY Earnings

Eli Lilly and Company (NYSE:LLY) – Equities researchers at Leerink Partnrs cut their Q3 2025 earnings estimates for shares of Eli Lilly and Company in a research note issued to investors on Wednesday, October 22nd. Leerink Partnrs analyst D. Risinger now anticipates that the company will post earnings of $5.87 per share for the quarter, down from their previous estimate of $6.58. Leerink Partnrs currently has a “Hold” rating on the stock. The consensus estimate for Eli Lilly and Company’s current full-year earnings is $23.48 per share. Leerink Partnrs also issued estimates for Eli Lilly and Company’s FY2025 earnings at $22.36 EPS.

Several other research analysts also recently weighed in on LLY. Leerink Partners reissued a “market perform” rating and issued a $715.00 target price on shares of Eli Lilly and Company in a research note on Thursday, August 7th. Erste Group Bank raised shares of Eli Lilly and Company from a “hold” rating to a “buy” rating in a research report on Tuesday, October 14th. JPMorgan Chase & Co. decreased their price target on shares of Eli Lilly and Company from $1,100.00 to $1,050.00 and set an “overweight” rating for the company in a research report on Tuesday, September 16th. HSBC raised their price objective on Eli Lilly and Company from $700.00 to $800.00 in a research note on Wednesday, October 1st. Finally, Deutsche Bank Aktiengesellschaft cut their target price on Eli Lilly and Company from $1,010.00 to $900.00 and set a “buy” rating on the stock in a research note on Monday, August 11th. One research analyst has rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating and nine have issued a Hold rating to the company’s stock. Based on data from MarketBeat, Eli Lilly and Company currently has an average rating of “Moderate Buy” and an average price target of $938.61.

Eli Lilly and Company Price Performance

Eli Lilly and Company stock opened at $825.86 on Monday. The firm’s 50-day simple moving average is $768.01 and its 200 day simple moving average is $768.56. Eli Lilly and Company has a 52 week low of $623.78 and a 52 week high of $935.63. The firm has a market capitalization of $781.65 billion, a PE ratio of 53.98, a P/E/G ratio of 1.23 and a beta of 0.47. The company has a quick ratio of 1.00, a current ratio of 1.28 and a debt-to-equity ratio of 1.86.

Eli Lilly and Company (NYSE:LLY) last issued its earnings results on Thursday, August 7th. The company reported $6.31 EPS for the quarter, topping the consensus estimate of $5.59 by $0.72. Eli Lilly and Company had a net margin of 25.91% and a return on equity of 92.72%. The company had revenue of $15.56 billion for the quarter, compared to analyst estimates of $14.40 billion. During the same period in the previous year, the firm earned $3.92 EPS. The business’s revenue was up 37.6% on a year-over-year basis. Eli Lilly and Company has set its FY 2025 guidance at 21.750-23.000 EPS.

Insider Activity

In other Eli Lilly and Company news, Director Jamere Jackson bought 200 shares of the stock in a transaction on Friday, August 8th. The shares were bought at an average price of $639.56 per share, with a total value of $127,912.00. Following the purchase, the director directly owned 9,402 shares in the company, valued at $6,013,143.12. The trade was a 2.17% increase in their position. The acquisition was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, CEO David A. Ricks bought 1,632 shares of the company’s stock in a transaction dated Tuesday, August 12th. The stock was acquired at an average price of $644.77 per share, for a total transaction of $1,052,264.64. Following the acquisition, the chief executive officer directly owned 546,601 shares in the company, valued at $352,431,926.77. This trade represents a 0.30% increase in their ownership of the stock. The disclosure for this purchase can be found here. In the last quarter, insiders have acquired 4,514 shares of company stock worth $2,894,841. 0.14% of the stock is owned by company insiders.

Institutional Investors Weigh In On Eli Lilly and Company

Several large investors have recently made changes to their positions in LLY. Hobbs Wealth Management LLC boosted its position in Eli Lilly and Company by 0.8% during the first quarter. Hobbs Wealth Management LLC now owns 1,459 shares of the company’s stock worth $1,205,000 after purchasing an additional 12 shares during the period. Hixon Zuercher LLC raised its stake in shares of Eli Lilly and Company by 0.7% in the first quarter. Hixon Zuercher LLC now owns 1,789 shares of the company’s stock valued at $1,477,000 after purchasing an additional 12 shares in the last quarter. O Brien Wealth Partners LLC raised its stake in shares of Eli Lilly and Company by 25.5% in the first quarter. O Brien Wealth Partners LLC now owns 59 shares of the company’s stock valued at $49,000 after purchasing an additional 12 shares in the last quarter. Ascent Capital Management LLC raised its stake in Eli Lilly and Company by 2.5% during the first quarter. Ascent Capital Management LLC now owns 495 shares of the company’s stock worth $409,000 after acquiring an additional 12 shares in the last quarter. Finally, Willner & Heller LLC raised its stake in Eli Lilly and Company by 1.5% during the first quarter. Willner & Heller LLC now owns 854 shares of the company’s stock worth $705,000 after acquiring an additional 13 shares in the last quarter. Institutional investors own 82.53% of the company’s stock.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.